While Sharifi et al. have identified the presence of HSD3B1 allelic variants in prostate cancer patients and how this may yield differing levels of downstream androgens, other works have further identified differences in mortality and outcomes of such patients in the context of allelic variants. Here, HSD3B1 is linked to prostate cancer.